Allogene Therapeutics (ALLO) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 65.7% versus a loss of 49.0%. Over five years, PLX leads with a +192.9% price change compared with -96.5% for ALLO. Protalix BioTherapeutics (DE) is the larger company by market cap ($244.5 million vs $217.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | PLX |
|---|---|---|
| Share price | $0.6277 | $2.90 |
| Market cap | $217.48M | $244.52M |
| 1-day change | -5.88% | -5.23% |
| YTD return | -54.18% | +61.11% |
| 1-year return | -48.97% | +65.71% |
| 5-year return | -96.51% | +192.93% |
| P/E ratio (TTM) | — | 12.08 |
| Forward P/E | — | 4.68 |
| EPS (TTM) | $-0.61 | $0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $52.74M |
| Revenue growth (YoY) | -100.00% | -1.23% |
| Net income (latest FY) | $-190.89M | $-6.60M |
| Gross margin | — | 48.82% |
| Operating margin | — | -10.43% |
| Net margin | — | -12.52% |
| 52-week high | $4.46 | $3.19 |
| 52-week low | $0.6192 | $1.65 |
| Distance from 52-week high | -85.93% | -9.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1333.81% | +313.79% |
| Average volume | 7.69M | 903.48K |
| Shares outstanding | 346.47M | 84.32M |
| Employees | 150 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed ALLO by 114.7 percentage points over the past year.
- Protalix BioTherapeutics (DE) grew revenue faster in its latest fiscal year (-1.23% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
ALLO vs PLX FAQ
Which is bigger, Allogene Therapeutics or Protalix BioTherapeutics (DE)?
Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $244.52M compared with $217.48M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or PLX?
PLX returned +65.71% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.